Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma

Katie E. Blise 1,2, Shamilene Sivagnanam 2,3, Grace L. Banik 3,4,5, Lisa M. Coussens 2,3 and Jeremy Goecks 1,2,6

There is increasing evidence that the spatial organization of cells within the tumor-immune microenvironment (TIME) of solid tumors influences survival and response to therapy in numerous cancer types. Here, we report results and demonstrate the applicability of quantitative single-cell spatial proteomics analyses in the TIME of primary and recurrent human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) tumors. Single-cell compositions of a nine patient, primary and recurrent \((n = 18)\), HNSCC cohort is presented, followed by deeper investigation into the spatial architecture of the TIME and its relationship with clinical variables and progression free survival (PFS). Multiple spatial algorithms were used to quantify the spatial landscapes of immune cells within TIMES and demonstrate that neoplastic tumor-immune cell spatial compartmentalization, rather than mixing, is associated with longer PFS. Mesenchymal \((\alpha SMA^+\)) cellular neighborhoods describe distinct immune landscapes associated with neoplastic tumor-immune compartmentalization and improved patient outcomes. Results from this investigation are concordant with studies in other tumor types, suggesting that trends in TIME cellular heterogeneity and spatial organization may be shared across cancers and may provide prognostic value in multiple cancer types.

npj Precision Oncology (2022) 6:10; https://doi.org/10.1038/s41698-022-00253-z

INTRODUCTION

Tumor microenvironments, comprising both neoplastic tumor cells and recruited stromal cells of various lineages, including a diverse assemblage of immune, mesenchymal, and vascular cells, play a key role in both de novo progression of tumors and regulating response to therapies. Numerous studies have reported that, in addition to the types and quantities of cells present in the tumor immune-microenvironment (TIME), the spatial organization of the TIME is prognostic for survival and response to therapy in multiple cancer types. Metrics that quantify this spatial organization can range from simple density ratios within specific tumor regions, such as the Immunoscore, a now commonly used biomarker for colorectal tumor staging, to more complex measures that account for the precise locations of specific cells relative to other cells, such as mixing scores and cellular neighborhood measures. These more advanced spatial quantifications are a result of emerging single-cell multiplex tissue imaging modalities, which provide detailed phenotypic and effector proteomic markers for each cell, while maintaining the spatial architecture of the tissue assayed. Knowing the precise locations of cells in the TIME enables a deeper understanding of how cells interact within the tumor, as both direct and indirect cell signaling mechanisms require cells to be near, if not directly adjacent to one another. This understanding can aid treatment decisions, as many therapies require spatial proximity of specific cell types for efficacy. Given that single-cell imaging technologies are still relatively new, there is much to be discovered regarding how the spatial organization of cells within the TIME relates to clinical outcome and may be used for patient stratification decisions for therapy.

Head and neck squamous cell carcinoma (HNSCC) is the sixth leading form of cancer worldwide, and it accounts for more than 100,000 deaths per year in the US alone. While patients harboring human papillomavirus (HPV) within neoplastic cells tend to exhibit a better prognosis, their HPV-negative \([\text{HPV}(-)]\) counterparts typically exhibit T cell suppressive TIMES and have a significantly greater risk of recurrence and shorter 3-year survival. There is a critical need to improve understanding of HNSCC TIMES to enable better patient stratification for therapy, as well as identify new targets that could be leveraged for therapeutic intervention to improve outcome, particularly for patients with HPV(−) tumors who currently lack promising therapeutic options. We previously developed a multiplex immunohistochemistry (mIHC) imaging platform to aid studies investigating the immune contexture of solid tumors and their response to therapies at the single-cell level. Using a sequential antibody staining protocol, detection of 12–30 proteins can be enumerated at single-cell resolution across a single formalin-fixed paraffin-embedded (FFPE) tissue section. This enables single-cell phenotyping of discrete leukocyte lineages, and importantly, reveals their spatial relationships with other cells in the tissue section. Utilizing this mIHC approach on a small cohort of eighteen HPV(−) primary and matched recurrent HNSCC tumor samples collected from nine patients, we previously reported immune contexts associated with disease recurrence, most notably that myeloid inflamed profiles in primary tumors exhibited shorter progression-free survival (PFS) compared to lymphoid inflamed profiles.

In this study, we have significantly extended our prior analysis of this cohort, focusing on tumor heterogeneity and compositional changes from primary to recurrent tumors, in addition to using multiple spatial algorithms to quantify the spatial organization of the TIMES. We then correlated these spatial features with PFS and identified TIME architectures that may be important for therapeutic decision making. Overall, we found increased neoplastic tumor-immune cell spatial compartmentalization in primary tumors to be associated with longer PFS. These tumors...
also contained alpha smooth muscle actin (αSMA⁺) cells with more organized structure located near T and B cells, as well as near cells involved in antigen presentation. Our results are concordant with those from other studies, indicating that the features identified herein are likely shared and prognostic across cancer types.

RESULTS
One to three regions of 2500² µm² from each of the nine patients primary and matched recurrent tumor resections (n = 18) were analyzed, for a total of 47 regions (Table 1 and Fig. 1a). For this study, we utilized a gating strategy with thirteen lineage or functional protein biomarkers to classify cells as neoplastic tumor cells, stromal cells (mesenchymal), or one of seven different leukocyte subtypes spanning lymphoid and myeloid lineages (Table 2 and Supplementary Fig. 1a). We investigated tumor heterogeneity both within and across patient samples, quantified the cellular spatial relationships within the TiME using a mixing score and performed a neighborhood clustering method to describe the association between TiME spatial architecture, clinical features, and PFS.

Single-cell proteomic analyses reveal varying degrees of tumor heterogeneity
To quantify how cellular composition varied across tumor regions, we assessed tumor heterogeneity at multiple levels, including intra-tumoral, intra-patient, and inter-patient cellular heterogeneity by calculating Kullback-Leibler (KL) divergences for each region, performing hierarchical clustering, and conducting a principal component analysis (PCA). The density of each cell type per region was measured for all eighteen tumor specimens by taking the count of each cell type divided by the measured tissue area in mm² (Fig. 1b, c). We then calculated the coefficient of variation per cell type for each tumor, and averaged these values to quantitatively describe the cell types contributing most to intra-tumoral heterogeneity within the cohort. The coefficient of variation is defined as the standard deviation divided by the mean, and it provides a normalized measure of variability for comparison across cell types with large differences in densities. On average, B cells exhibited the greatest coefficient of variation across the cohort relative to other cell types (Table 3). This is likely due to the fact that B cells were frequently observed to be spatially clustered together, resulting in regions of either high B cell density or low B cell density despite being collected from the same tumor (Supplementary Fig. 1b).

To further quantify and assess tumor heterogeneity both within and across patients, we calculated the KL divergence of each tumor region from five average cell type distributions. KL divergence is a relative measure of how similar two distributions are, with larger values reflecting less similarity between the distributions and smaller values reflecting more similarity between the distributions. This measure has been used previously to quantify tumor heterogeneity⁶. By calculating and comparing the divergences of each tumor region from multiple average cell type distributions, we were able to assess heterogeneity within and across tumors and patients. Overall, we observed that heterogeneity was lower across regions from the same tumor and tumors from the same patient (primary or recurrent), while higher across tumors from different patients. This is evidenced by smaller intra-tumoral and intra-patient KL divergence values for the majority of tumor regions (Fig. 1d).

The cellular distributions used to calculate the five KL divergence values per tumor region were (1) the average cellular distribution across all regions sampled from the same tumor ("Intra-Tumor (P or R only)"); (2) the average cellular distribution across the patient’s primary and recurrent tumors ("Intra-Patient (P

### Table 1. Patient and tumor characteristics.

| Patient ID | Anatomic site of resection | Primary tumor TNM stage | Therapy following primary resection | Smoking history | Alcohol history | HPV status | Progression-free survival (days) |
|------------|----------------------------|--------------------------|-----------------------------------|----------------|----------------|-----------|---------------------------------|
| 1          | Oral Cavity                | 2                        | Cisplatin                         | Yes            | Yes            | Negative  | 804                             |
| 2          | Oral Cavity                | 4                        | Cetuximab                         | Yes            | Yes            | Negative  | 123                             |
| 3          | Oral Cavity                | 1                        | Cisplatin                         | Yes            | No             | Negative  | 1447                            |
| 4          | Oral Cavity                | 1                        | Cetuximab + Radiation             | Yes            | No             | Negative  | 246                             |
| 5          | Oropharynx                 | 4                        | Cisplatin                         | Female         | White          | No        | 188                             |
| 6          | Oropharynx                 | 4                        | Cetuximab + Radiation             | Female         | Asian          | No        | 202                             |
| 7          | Larynx                     | 4                        | Cisplatin + Cetuximab             | Female         | Asian          | No        | 188                             |
| 8          | Larynx                     | 3                        | Cisplatin + Cetuximab + Radiation | Female         | White          | Yes       | 409                             |
| 9          | Larynx                     | 4                        | Cisplatin + Cetuximab + Radiation | Female         | White          | Yes       | 1033                            |

*Table 1.* Patient and tumor characteristics. Published in partnership with The Hormel Institute, University of Minnesota
and R)]; (3) the average cellular distribution across all tumors in the cohort collected from the same timepoint ["Inter-Patient (P or R only)"]; (4) the average cellular distribution across all tumors in the cohort resected from the same anatomic site ["Inter-Patient (Same Anatomic Site)"], and; (5) the average cellular distribution across all tumors collected from all patients in the cohort, regardless of primary or recurrent status or anatomic site ["Inter-Patient (all)"]. By comparing the relative KL divergence values to each other, we found tumor regions to be more similar to regions sampled from the same tumor and patient than regions collected.
Fig. 1  Heterogeneity across patients and tumor regions. **a** Cohort and tissue region selection overview. One to three regions of 2500 µm² were assayed with mIHC per eighteen tumor resections and are represented by the green boxes in the tissue images. Black scale bar = 2500 µm. **b** Density (cells/mm²) of each cell type present per individual primary (P) and recurrent (R) tumor. Each dot represents a single tumor region (n = 47). **c** Density (cells/mm²) of each immune cell type present per individual primary (P) and recurrent (R) tumor. Each dot represents a single tumor region (n = 47). **d** Box plot of the Kullback–Leibler divergences from a single tumor region's cellular distribution compared to: the tumor's average cellular distribution [Intra-Tumor (P or R only)], the patient’s average cellular distribution [Intra-Patient (P and R)], the cohort’s average cellular distribution across tumors of the same anatomic site [Inter-Patient (Same Anatomic Site)], the cohort’s average cellular distribution across tumors from different anatomic sites [Inter-Patient (all)]. **e** Heatmap of cellular composition across tumor regions. Rows are individual tumor regions that are ordered by the hierarchical clustering of their cellular composition. Columns are the cell types used as clustering features. Composition was normalized using a log10 + 1 transformation before clustering. Leftmost three columns are color coded by patient, tumor timepoint, and anatomic site. **f** Principal component analysis on cellular density following a log10 + 1 transformation. Each point (n = 47) represents one tumor region and is colored by patient. The shape of each point denotes primary or recurrent status. **g** Principal component analysis on cellular density following a log10 + 1 transformation. Each dot (n = 47) represents one tumor region and is colored by anatomic resection site.

To further investigate intra-patient heterogeneity, we performed unsupervised hierarchical clustering on the 47 tumor regions based on their normalized density composition (Fig. 1e). We found that two patients (3, green; 7, pink) contained all tumor regions clustering together, independent of primary or recurrent state. These patients also had the smallest intra-patient KL divergence values (Fig. 1d), indicating that the cell densities of these patients’ primary and recurrent tumors were similar to each other. Three patients (2, orange; 4, red; 9, yellow) contained nearly all regions clustered together. The remaining four patients’ tumors exhibited greater degrees of intra-patient heterogeneity, as demonstrated by the distance between primary and recurrent tumor regions on the clustered heatmap (Fig. 1e). Overall, we found that regions evaluated from the same patient tended to cluster together more than regions evaluated from different patients (Fig. 1e), indicating increased heterogeneity between patients as compared to between samples from the same patient. We also examined whether tumor regions clustered by the anatomic resection site and found that the clusters formed did not group by site. These results, in addition to those of our KL divergence analyses, indicate that anatomic site was likely not the main contributor of cellular heterogeneity in this cohort. PCA results also supported these observations (Fig. 1f, g).

**Table 2.** mIHC cell phenotype classification.

| Cell phenotype               | Antibody markers |
|------------------------------|------------------|
| CD8+ T Cell                 | CD20+ CD3+ CD8+ |
| CD4+ T helper               | CD3+ CD20+ CD8+ |
| CD4+ regulatory T cell      | CD20+ CD3+ CD8+ |
| B Cell                      | CD20+ CD66B CD68+ |
| Macrophage                  | CD45+ CD20+ CD3+ |
| Antigen presenting cell     | CD45+ CD20+ CD3+ |
| Other immune                | CD45+ CD20+ CD3+ |
| uSMA+ mesenchymal           | CD3+ CD68+ CD66B |
| Neoplastic tumor            | CD45+ CD20+ |
| Functional markers          | PD-1, PD-L1, Ki-67 |

**Table 3.** Coefficient of variation.

| Cell phenotype               | Average coefficient of variation |
|------------------------------|----------------------------------|
| B Cell                       | 0.658                            |
| Macrophage                   | 0.563                            |
| uSMA+ mesenchymal            | 0.545                            |
| Neoplastic tumor             | 0.541                            |
| Granulocyte                  | 0.523                            |
| Antigen presenting cell      | 0.519                            |
| Other immune                 | 0.402                            |
| CD8+ T cell                  | 0.384                            |
| CD4+ T helper                | 0.376                            |
| CD4+ regulatory T cell       | 0.311                            |

from tumors of other patients. Notably, we found no significant difference between “Inter-Patient (Same Anatomic Site)” and “Inter-Patient (all),” indicating that tumor regions diverged by the same degree from regions sampled at the same anatomic site as they did from regions sampled at all three anatomic sites (oral cavity, oropharynx, and larynx) of the head and neck region (Fig. 1d). Finally, given the large proportion of neoplastic tumor cells comprising the TiME for many of the tumor regions, we assessed KL divergence using only the distribution of immune cells present and found similar results (Supplementary Fig. 1c). This indicates that immune cell composition is more similar within regions from the same patient than across regions collected from different patients.

**TIME cellular composition altered by therapy**

Multiple studies have reported differences in TiME cellular makeup and tumor clonal diversity between primary and recurrent tumors. To assess whether any immune contexture changes occurred following post-operative therapy in our cohort, we analyzed the cellular composition of primary tumors as compared to their recurrent tumors. All patients received a combination therapy of cisplatin and/or cetuximab accompanied by radiation following surgical resections of their primary tumors. We used the average density of each cell type present across regions for a given tumor and compared primary tumor composition to their matched recurrent tumor composition. While we did not observe any significant differences in cell density between primary and recurrent tumors (p > 0.112), we did find that all patients experienced a decrease in the density of B cells from their primary to recurrent tumors (Fig. 2a, b). This result is supported by a recent study that found that a large cohort of HNSCC patients experienced a decline in B cells from primary to recurrent tumors, and this reduction was dependent upon patients receiving adjuvant chemoradiotherapy. We found no common differences across all patients for any other cell type, although eight of the nine patients saw a decrease in the density of neoplastic tumor cells from their primary to recurrent tumors (Fig. 2b). We then assessed whether patients exhibited similar compositional differences in primary and recurrent TiMEs by performing unsupervised hierarchical clustering on the normalized average...
Fig. 2  Tumor cellular composition changes following therapy. a Box plot showing the average density of each cell type split by primary and recurrent status. Each dot represents the density of that cell type for one tumor, averaged across regions (n = 9 primary tumors, n = 9 recurrent tumors). Boxes = quartile 1 (Q1) to quartile 3 (Q3); whiskers = smallest and largest datapoints within 1.5*interquartile range (IQR) +/- Q3/Q1; solid line = median. b Line plots showing the change in cellular composition from primary to recurrent tumors for each cell type. Each dot represents the density of that cell type for one tumor, averaged across regions. Lines are colored by patient. c Heatmap of average change in cellular composition from primary to recurrent tumors for each patient. Rows are individual patients that are ordered by the hierarchical clustering of their change in TiME cellular composition (averaged across regions). Columns are the cell types used as clustering features. Compositional change was normalized [-1,1] before clustering (see “Methods” section). Leftmost two columns are color coded by patient followed by therapy administered. d Box plot showing the average change in density of each cell type for each patient (n = 9) colored by short-term or long-term progression free survival, splitting on median progression-free survival. Boxes = Q1 to Q3; whiskers = smallest and largest datapoints within 1.5*IQR +/- Q3/Q1; solid line = median; dotted line = mean.

difference in cellular composition for each cell type. This resulted in two groups of patients (Fig. 2c). Interestingly, the two patients that received cetuximab (2, orange; 5, purple), rather than cisplatin, clustered together within one of these groups and were the only two patients to experience a decrease in the density of every cell type following therapy. Across the cohort these patients had the greatest decrease in the density of macrophages, granulocytes, and other CD45+ immune cells present from their primary tumors to their recurrent tumors following therapy (Fig. 2b, c). Interestingly, the one patient who received both cisplatin and cetuximab (7, pink) was present in the other cluster from the two patients who received only cetuximab. This was the only patient to experience an increase in the density of neoplastic tumor cells (Fig. 2b, c). This patient also experienced the second largest increase in CD8+ T cells as well as the greatest decrease in CD4+ regulatory T cells, potentially indicating a pro-inflammatory
response to—or despite—increased neoplastic tumor cell density. Altogether, these results indicate that shared trends in TiME composition changes from primary to recurrent tumors specific to therapy exist, and regardless of therapy, all patients exhibited a decrease in B cells from primary to recurrent tumors.

Approximately half \((n=4)\) of the patients in the cohort experienced an increase in CD8\(^+\) T cell density while the other half \((n=5)\) experienced a decrease in CD8\(^+\) T cell density following therapy. This was the only cell type that increased in density for nearly half of the cohort and decreased for the other half. To determine if there was a survival advantage for patients that experienced this increase, we split our cohort into short-term or long-term survivor groups using median PFS and observed that all patients, who experienced an increase in CD8\(^+\) T cell density from their primary to recurrent tumors were long-term survivors (Fig. 2d). Interestingly, the density of CD8\(^+\) T cells in the primary
that cell type for one region (n = 18). Each dot (n = 47) represents the mixing score for one tumor region and is colored according to the region’s spatial architecture. The average spatial architecture designation for the overall tumor is printed above each box. Boxes = Q1 to Q3; whiskers = smallest and largest datapoints within 1.5*IQR =–/– Q3/Q1; solid line = median; dotted line = mean. e Box plot showing the mixing score of each tumor region split by the anatomic site of its resection. Boxes = Q1 to Q3; whiskers = smallest and largest datapoints within 1.5*IQR =–/– Q3/Q1; solid line = median. p-value calculated using a one-way ANOVA multi-group significance test followed by a Tukey honestly significant difference post-hoc test. d Kaplan–Meier curve of progression free survival for patients split by the mixing score of their primary tumors. Patients were split on the median value. p-value calculated using the log-rank test. e Principal component analysis on cellular density following a log10 + 1 transformation. Each dot (n = 47) represents one tumor region and is colored according to the region’s spatial architecture. f Box plot showing the density of each cell type split by the tumor region’s spatial architecture. Each dot represents the density of that cell type for one region (n = 47 per cell type). Boxes = Q1 to Q3; whiskers = smallest and largest datapoints within 1.5*IQR =–/– Q3/Q1; solid line = median; dotted line = mean. Statistical significance calculated using independent one-tailed t-tests for cell types whose differences follow a normal distribution and non-parametric one-tailed t-tests (Mann–Whitney U-test) for cell types whose differences do not follow a normal distribution. P-values were corrected using the Benjamini–Hochberg procedure. g PD-1 expression on CD8+ T cells, CD4+ T helper cells, and B cells by spatial architecture. Each dot represents the percentage of each cell type positive for PD-1 across the overall tumor. Each dot represents the percentage of each cell type positive for PD-1 for a single tumor region. h Ki-67 expression on APCs by spatial architecture. Each dot represents the percentage of cells positive for Ki-67 for a single tumor region (n = 45, excluding cold regions). Boxes = Q1 to Q3; whiskers = smallest and largest datapoints within 1.5*IQR =–/– Q3/Q1; solid line = median. P-values calculated using a Mann–Whitney U-test and corrected across all cell types using the Benjamini–Hochberg procedure. i Bar chart showing the density of αSMA+ mesenchymal cells present per tumor region. Bars are ordered by αSMA+ cell density and are colored according to the region’s spatial architecture.

Tumor alone did not associate with PFS (p = 0.829). Prior research has revealed that increased CD8+ T cell abundance in the primary tumor is associated with better outcomes in HNSCC29–33. However, these studies largely included HPV-positive HNSCCs, which is more often associated with greater densities of CD8+ T cells and improved survival12–24, thus unsurprising that our results differ. However, our results are concordant with a recent study in HNSCC that reported longer survival was associated with patients who had experienced an increase in CD8+ tumor-infiltrating lymphocytes from their primary to recurrent tumor34. Another study in HNSCC found a similar trend between increased CD8+ T cell infiltration, longer survival, presence of specific neoantigens, and increased cytotoxic activity in recurrent tumors35. Notably, the four patients in our cohort that experienced the greatest decrease in CD8+ T cell density in recurrence had TNM stage 4 primary tumors, while patients that experienced an increase in CD8+ T cell density in recurrence included TNM stages 1, 2, 3, and 4.

Quantifying the spatial organization of neoplastic and immune cells

Prior studies reported the abundance of various cell types, including CD8+ T cells39, CD4+ regulatory T cells46, and macrophages47 to be associated with survival in HNSCC. We analyzed the average density of each cell type across primary tumors for their correlations with PFS, but found no significant association with PFS for any single cell type (p > 0.159). Given the prognostic potential of TIME cellular spatial organization as has been reported in other cancer types12–13, we quantified the spatial organization of cells within tumor regions and examined the association of the spatial features with clinical outcome.

We first deployed a mixing score, used previously to analyze immune cell spatial compartmentalization in triple negative breast cancers42. The mixing score measures the enrichment of neoplastic tumor-immune cell proximity relative to immune-immune cell proximity within a set distance. We quantified the number of immune and neoplastic tumor cells within 15 µm of each other, divided by the number of immune cells within 15 µm from another immune cell. Each region was labeled as mixed or compartmentalized using the median mixing score value for all primary tumors as the threshold (Fig. 3a, b; see “Methods” section). This threshold classified tumor regions as mixed if at least one neoplastic tumor cell was within 15 µm from an immune cell for approximately every ten immune cells within 15 µm from another immune cell. Tumor regions were considered compartmentalized when this ratio was smaller. Regions with fewer than 250 CD45+ immune cells per 8002 µm2 present were labeled as cold, utilizing the same immune cell density threshold from the original study4. Of the 47 total tumor regions, 25 were mixed, 20 were compartmentalized, and two were cold.

After calculating the mixing score for each region, we examined the spatial heterogeneity of our cohort. Our tumor compositional heterogeneity analyses revealed that intra-tumoral and intra-patient heterogeneity was less than inter-patient heterogeneity. To determine whether this observation held for spatial organization heterogeneity, we compared each region’s mixing score to five groups of average mixing scores, which were computed from the same five groups as the analysis in Fig. 1d: Intra-tumor (P or R only), Intra-patient (P and R), Inter-patient (P or R only), Inter-patient (Same Anatomic Site), and Inter-patient (all). Contrary to our analysis in Fig. 1d, the mixing score is only one feature, not a distribution of features, thus we used the difference in mixing scores, rather than the KL divergence. In addition, we calculated the absolute values of these differences as a way to normalize the data in order to capture the degree of difference in spatial organization, allowing us to subsequently test for differences across the five levels of heterogeneity. We found there to be less intra-tumoral heterogeneity than inter-patient heterogeneity (Supplementary Fig. 2a). This result indicates that, in terms of neoplastic tumor-immune cell mixing, tumor regions resemble regions sampled from the same tumor more than regions sampled from tumors of other patients.

We then considered whether tumor regions sampled from the same anatomic site differed in their spatial organization and found that of the three anatomic sites, tumor regions from the oral cavity contained significantly different average mixing scores than tumor regions from the larynx (p = 0.016, Fig. 3c). No significant differences were found in average mixing scores between the oral cavity and the oropharynx or the larynx and the oropharynx. Regions from larynx tumors did exhibit a greater range of mixing scores than oral cavity or oropharynx (Fig. 3c) indicating that larynx tumors exhibit greater spatial heterogeneity in terms of neoplastic tumor-immune cell proximity. We found no significant difference in the mixing scores of primary versus recurrent tumors (Wilcoxon signed rank test, p = 0.441).
Spatial compartmentalization associated with longer progression free survival

To investigate how spatial mixing correlated with patient outcome, we averaged the mixing scores across regions and assigned a final mixing score and spatial label for each tumor. Patients with more compartmentalization between neoplastic cells and immune cells in their primary tumors exhibited significantly longer PFS than those with greater mixing between these cell types ($p = 0.032$, Fig. 3d). We then examined how the average mixing score of the tumors related to the TNM stage and...
anatomic site of each primary tumor. Four of the five mixed primary tumors were T1N0 stage 4, and one was T1N1 stage 1. The four compartmentalized primary tumors were TNM stages 1, 2, 3, and 4. All anatomic sites were present in both mixed and compartmentalized spatial architecture groups (mixed: 2 oral cavity, 1 oropharynx, 2 larynx; compartmentalized: 2 oral cavity, 1 oropharynx, 1 larynx), indicating no single anatomic site had predominantly mixed or compartmentalized spatial architecture.

Spatial architecture associated with cellular composition
We next explored how cellular composition related to spatial organization, in an effort to explain the association found between mixing score and PFS. By colorizing the initial PCA on TIME composition by mixing score, we found that tumor regions from the same mixing group clustered together (Fig. 3e). Due to this association between cellular composition and spatial organization, we wondered whether certain cell types would be more frequent in mixed or compartmentalized tumors. Given how the mixing score is calculated, we hypothesized that compartmentalized tumor regions would have greater densities of immune cells than mixed regions, while mixed tumor regions would have greater densities of neoplastic tumor cells than compartmentalized tumor regions, and found this to be the case (Fig. 3f). Namely, compartmentalized tumor regions had greater densities of CD4+ T helper cells (p = 0.016), B cells (p = 0.048), antigen presenting cells (APCs) (p = 0.037), and other CD45+ immune cells (p = 0.048) than mixed tumor regions. Given the role of CD4+ T helper cells, B cells, and other MHCII+ immune cells in antigen presentation, these results could indicate enhanced antigen presentation in compartmentalized tumor regions as compared to mixed regions. Conversely, mixed tumor regions contained greater densities of neoplastic tumor cells than compartmentalized regions (p < 0.001).

We further examined associations between functional phenotypes of leukocytes and mixing scores for each tumor region. Mixed regions contained a greater proportion of lymphocytes, including CD8+ T cells (p = 0.023), CD4+ T helper cells (p = 0.017), and B cells (p = 0.016), expressing the immunoregulatory protein programmed death ligand (PD)-1 than compartmentalized regions (Fig. 3g). PD-1 is recognized as an indicator of T cell antigen experience, whereas its expression on B cells has been reported to suppress T cell effector function38,39, indicating a suppressive and potentially dysfunctional immune environment in mixed tumors. On the contrary, compartmentalized regions contained a greater proportion of APCs expressing the proliferation marker Ki-67 than mixed regions (p = 0.032, Fig. 3h), supporting the notion that antigen presentation is a key feature of compartmentalized regions. We performed a bootstrapping analysis to confirm the robustness of these results and demonstrate that no one tumor was biasing the functional marker results (Supplementary Fig. 2b-e).

In addition to identifying differences between spatial architectures and their respective immune and neoplastic tumor cell densities and functional marker expressions, we found that tumor regions with more compartmentalization between neoplastic cells and immune cells also contained greater densities of αSMA+ mesenchymal cells, as compared to those with higher mixing (p = 0.002, Fig. 3f). This result was intriguing because these cells were not included when computing the mixing score, yet there is a clear association between αSMA+ cell density and the tumor’s spatial organization (Fig. 3i).

αSMA+ mesenchymal spatial cellular neighborhoods reveal spatial landscapes associated with progression free survival advantage
Given the relationship between mixing score and αSMA+ mesenchymal cell density, we deployed a cellular neighborhood clustering analysis to identify which cell types were spatially proximal to αSMA+ cells across tumors in order to gain a better understanding of whether these cells were contributing to the neoplastic tumor-immune spatial compartmentalization observed. This analysis first involved calculating neighborhoods, which were defined as physical groupings of cells within a set distance threshold from a seed cell (Fig. 4a). Each cell within the distance threshold was deemed a neighbor of the seed cell, contributing to that seed cell’s neighborhood’s composition. After identifying neighborhoods for each seed cell present across all tumor regions, neighborhoods were grouped with K-means clustering, using the fraction of each cell type present in the neighborhoods as the clustering features. This revealed clusters of αSMA+ cell neighborhoods with similar cellular makeups across all tumor regions.

We applied a neighborhood clustering analysis with αSMA+ cells as the seed cells with a distance threshold of 30 µm, as this produced neighborhoods with an average of approximately ten neighbor cells. A recent study involving cellular neighborhood analyses employed a method that selected the ten nearest spatial neighbors of the seed cell, regardless of the distance between the seed cell and its neighbors7. By setting a distance threshold of 30 µm, our method required the cells be close, if not directly touching, while still capturing enough neighbors to cluster on. Any αSMA+ cell that did not have any neighbors was removed from downstream clustering analyses. Clustering results yielded seven groups, each different in their average composition of αSMA+ neighborhoods (Fig. 4b). Clusters 1 and 2 contained mostly other αSMA+ cells comprising the neighborhoods; in fact, cluster 1 was almost exclusively made up of αSMA+ cells. Cluster 3 contained the greatest proportion of neoplastic tumor cell neighbors. Clusters 4, 5, 6, and 7 were all comprised of roughly 75% immune cells as neighbors, although they differed in the...
types of immune cells present. Cluster 4 was defined by a majority of other CD45+ immune cells not explicitly defined within our gating strategy. To elucidate marker expression within these other CD45+ cells, we performed a post-hoc t-distributed stochastic neighbor embedding (t-SNE) analysis on cells classified as “other immune”, and found them to contain a large population of CD163+ cells and a smaller population of mast cells (tryptase+) (Supplementary Fig. 3a). Cluster 5 contained primarily CD8+ T cells as the dominant immune population. Cluster 6 consisted of CD4+ T helper cells, B cells, and the greatest proportion of APCs of any cluster. Finally, cluster 7 was defined by its large proportion of granulocytes.

We confirmed that no single tumor region, entire tumor, or patient dominated any of the aSMA+ neighborhood clusters by examining the percent contribution of each of the seven clusters per 47 tumor regions, eighteen tumors, and nine patients. While clusters were present in varying degrees across tumor regions, our results indicated that no region (Supplementary Fig. 3b), tumor (Supplementary Fig. 3c), or patient (Supplementary Fig. 3d) was solely responsible for giving rise to any of the clusters. We also confirmed that all seven clusters were present in tumors collected from each of the three anatomic sites (Supplementary Fig. 3e), as well as each of the four TNM stages (Supplementary Fig. 3f).

To identify groups of patients with primary tumors of similar aSMA+ cellular neighborhoods, we performed unsupervised hierarchical clustering on the normalized average aSMA+ cellular neighborhood composition across the nine primary tumors. This resulted in two groups of patients, differing in proportional compositions of aSMA+ cellular neighborhoods (Fig. 4c). On average, both groups had roughly 20% of their aSMA+ cells assigned to cluster 2 and roughly 10% of their aSMA+ cells assigned to cluster 5 (Fig. 4d). However, the two groups differed in that group 1 (blue) included patients with aSMA+ cells predominantly assigned to clusters 1 and 6, meaning their aSMA+ cells were primarily surrounded by CD4+ T helper cells, B cells, and other aSMA+ cells. On the contrary, group 2 (orange) included patients with more of their aSMA+ cells assigned to clusters 3, 4, and 7, meaning their aSMA+ cells were mostly surrounded by neoplastic tumor cells, other immune cells, and granulocytes. Consistent with our results, visualization of tissue regions illustrates primary tumors in group 1 containing more aSMA+ stromal cells overall, frequently neighboring CD4+ T helper cells and B cells, with greater MHCII positivity (Fig. 4e). Primary tumors in group 2 contained less structured aSMA+ stromal cells, fewer neighboring immune cells, and less MHCII positivity, differences that were strikingly apparent in the mHIC stained tissue images (Fig. 4e). Despite both groups containing nearly equal proportions of CD8+ T cells neighboring aSMA+ cells, group 1 contained higher densities of CD8+ T cells and increased MHCII positivity as compared to group 2 (Fig. 4e).

To determine if the composition of aSMA+ cellular neighborhood groups was correlated with clinical outcome, we performed a survival analysis on the two groups of patients. We found that patients in group 1 had significantly longer PFS than patients in group 2 (p = 0.047, Fig. 4f). Patients in group 1 had primary tumors annotated as TNM stages 1, 2, 3, and 4, while patients in group 2 had four primary tumors annotated as TNM stage 4 and one annotated as TNM stage 1. Tumors from all three anatomic sites were represented in both groups. An analysis of the proportions of aSMA+ neighborhood clusters present in each of the nine primary tumors revealed the varying degrees to which each of the seven clusters were present in each of the tumors (Fig. 4g). Notably, we found there to be a positive correlation between the presence of clusters 1 and 6 (r = +0.69) as well as clusters 4 and 7 (r = +0.66). We found negative correlations between the presence of clusters 1 and 4 (r = -0.88), clusters 3 and 6 (r = -0.69), and clusters 6 and 7 (r = -0.65). Finally, we found the two groups resulting from hierarchical clustering to be associated with mixing status. Specifically, group 1 consisted of 75% compartmentalized tumors, and group 2 consisted of 80% mixed tumors. Overall, these results describe interesting spatial relationships between immune cells, mesenchymal stroma, and neoplastic tumor cells, indicating increased antigen presentation and immune activity associated with compartmentalization and progression-free survival.

DISCUSSION
The significant role that TiME cellular composition plays in tumor progression and response to therapy has been accepted for over a decade.60 However, recent findings powered by single-cell proteomics imaging technologies have found that the spatial organization of the cells present in the TiME also plays a critical role.13 TiME spatial quantifications are just beginning to provide novel insights into tumor biology, and thus it is still unclear exactly which spatial features are important in dictating response to therapy or clinical outcome, as well as whether these features are shared across cancer types, and how they could be leveraged for therapeutic decisions and patient stratification. Here, we leveraged single-cell spatial proteomics data generated by our mHIC immunoassay-based imaging platform to quantitatively assess the TiME of nine matched primary and recurrent HPV(-) HNSCCs in order to demonstrate the use of spatial features in disease prognosis. Our results on this cohort of nine patients provide insight into the heterogeneity and spatial landscape of HPV(-) HNSCCs, and highlight possible TiME spatial landscapes that may impact clinical outcome across cancer types.

We found concordance between the results from our heterogeneity and composition analyses and those from several other studies. Our results are similar to a study that clustered HNSCC biopsies based on their neoplastic and immune gene signatures as determined by RNA-sequencing, and reported that samples from the same patient were more similar to each other than samples from different patients.41 This trend has also been observed across cancer types, including melanoma12, hepatocellular carcinoma13, pancreatic ductal adenocarcinoma14, and breast cancer15. Moreover, we found that patients who experienced an increase in CD8+ T cell density from their primary to recurrent tumors were associated with improved PFS, which has previously been reported in head and neck cancer43,45. Conversely, patients experiencing the greatest decrease in CD8+ T cell density in recurrence had TNM stage 4 primary tumors. This could indicate that later staged primary tumors are better equipped to evade immune attack in recurrence, and a therapy to elicit an anti-tumor immune response may be beneficial.

Despite the fact that HPV(-) HNSCCs often contain limited immune infiltrates22, our analyses revealed significant differences in the immune cell spatial organization within these tumors that were associated with progression-free survival, highlighting the importance of considering the spatial context of the TiME. Most strikingly, patients whose primary tumors contained more compartmentalization between their neoplastic tumor cell and immune cell populations demonstrated longer PFS. This correlation was also identified in a similar analysis of triple negative breast cancer patients, indicating that a compartmentalized spatial architecture may play a favorable role in survival across cancer types. Our analyses of TiME composition and functional marker expression indicate there is likely more antigen presentation and less immunoregulation in regions of compartmentalization rather than in regions of mixing. This favorable immune landscape in compartmentalized tumors may contribute to improved survival. On the contrary, four of the five of the mixed primary tumors were classified as TNM stage 4, which may contribute to shortened survival for these patients. However, given that compartmentalized tumors were not all classified as an early TNM stage and instead ranged from TNM stage 1 to 4, it is difficult to determine the exact association between neoplastic
tumor and immune cell mixing versus TNM stage, and further investigation is warranted to understand these correlations and impact on prognosis.

Prior studies have identified a mesenchymal HNSCC subtype\textsuperscript{46,47}; our αSMA\textsuperscript+ mesenchymal cellular neighborhood analyses highlight the importance of considering how these cells are organized within the TIME, beyond simply considering their presence in the tumor. This could reveal more precise mesenchymal subtypes for improved stratification for patient care. αSMA is a common marker for cancer-associated fibroblasts (CAFs)\textsuperscript{20,48}, whose presence in tumors, including HNSCC, tends to be associated with tumor progression, metastasis, and resistance to therapy\textsuperscript{49–54}. However, despite compartmentalized tumors having increased αSMA\textsuperscript+ cell density, patients with compartmentalized primary tumors demonstrated longer PFS, which indicates that the spatial organization of αSMA\textsuperscript+ cells may be related to their function.

We found αSMA\textsuperscript+ cells neighboring immune cells in both mixed and compartmentalized primary tumors, but the types of immune cells near αSMA\textsuperscript+ cells differed. This is interesting, as emerging research has found that CAFs, which are often defined by their expression of αSMA, can modulate immune cell function within the TIME. With our mHLC platform we were able to identify the differences in the types of immune cells neighboring αSMA\textsuperscript+ cells and relate these differences to survival, supporting recent research on the impact of CAFs on various immune cell populations. A recent study in melanoma found CAFs to be instrumental in aiding tertiary lymphoid structure (TLS) development\textsuperscript{55}; TLS are defined by their large concentration of B cells surrounded by T cells, and their presence in tumors is associated with improved patient outcome\textsuperscript{43,56,57}. In compartmentalized tumors, we noticed the αSMA\textsuperscript+ cells to be more structured and located neighboring dense pockets of T cells and B cells, perhaps indicating the formation of TLS. Although this antibody panels did not include a biomarker for high endothelial venules to confirm presence of TLS, our results support the notion that CAF-lymphocyte interactions can be clinically beneficial.

Conversely, patients with predominantly mixed primary tumors and shorter PFS contained αSMA\textsuperscript+ cells primarily located near granulocytes and other CD45\textsuperscript+ immune cells, many of which were likely CD163\textsuperscript+ myelomonocytic cells or mast cells. CD163 is a marker for scavenger receptor activity and is commonly used to demark pro-tumor type tumor-associated macrophages and monocytes. Supporting these findings, a study in oral squamous cell carcinoma found the presence of CAFs to be associated with increased presence of CD163\textsuperscript+ macrophages and worse survival\textsuperscript{58}. Another study reported CAFs to be correlated with an increase in monocyte expression of CD163, which in turn suppressed T cell proliferation and increased neoplastic cell proliferation in breast cancer\textsuperscript{59}. Mast cells mediate innate and acquired immune response as a part of the myeloid lineage. They have been reported to facilitate neo-vascularization and tumor dissemination in HNSCC, and found to be associated with increased angiogenesis in advanced HNSCC\textsuperscript{60}. However, interactions between mast cells and CAFs is largely unknown; our results indicate this interaction may be associated with increased neoplastic density and worse PFS. Of note, a recent study in melanoma and pancreatic adenocarcinoma found neutralophils, a subclass of granulocytes, to exert pro-tumor effects when in the presence of CAFs\textsuperscript{61}, and another study found the combined presence of neutrophils and CAFs to be associated with shortened survival in gastric adenocarcinoma\textsuperscript{62}.

Finally, patients with predominantly mixed primary tumors and shorter PFS were found to contain fewer overall stromal cells and greater proportions of those αSMA\textsuperscript+ cells neighboring neoplastic tumor cells. It has been reported that neoplastic tumor cells in direct contact with CAFs move along tracks laid by the CAFs in the extracellular matrix, promoting tumor growth\textsuperscript{63,64}. It is possible that αSMA\textsuperscript+ cells in mixed tumors may provide avenues for neoplastic tumor cells to transit, thus leading to more advanced tumor progression. Overall, spatial analyses herein deepened our understanding of neoplastic tumor and immune cell organization relative to each other, and how this organization is related to αSMA\textsuperscript+ cells working in tandem with many cells, beyond single cell–cell interactions, to impact TIME organization, and ultimately, clinical outcome. The conclusions from our spatial analyses and their relationship to clinical variables are summarized in Fig. 5.

The concordance found among results herein and those of the aforementioned studies provides orthogonal support for our conclusions and indicates that single-cell heterogeneity and
spatial organization of tumors may share similarities across different types of cancer and across different molecular assays. Our spatial analyses demonstrate the use of various algorithms to quantify the spatial landscape of tumors using single-cell imaging data. Further, our computational methods provide a framework for future single-cell imaging analyses, as they are applicable to any multiplex imaging assay, including miHC, co-detection by indexing technology (CODEX), cyclic immunofluorescence, and imaging mass cytometry. Our results highlight several spatial architectures that may help guide precision medicine approaches for HPV(−) HNSCC patients, including architectures that may help stratify patients who may have shorter PFS, and thus warrant more aggressive therapy or clinical follow-ups. While our results provide evidence that the spatial organization of HPV(−) HNSCC tumors correlates with clinical outcome, future studies with larger cohorts will be needed to evaluate the strength and validity of our observations. Studies with greater representation of anatomic site and stage are also needed to assess the prognostic value of the spatial features identified in this HNSCC cohort. Despite these limitations, this study demonstrates practical analysis strategies that elucidate spatial architecture features for potential use in precision medicine.

**METHODS**

**Multiplex immunohistochemistry data generation**

miHC is an immunohistochemical-based imaging platform that evaluates sequentially stained immune lineage epitope-specific antibodies for immunodetection on FFPE tissue sections. Images were stained and processed as described in our previous report. A table of antibodies, species, vendor, and concentration used in staining are previously reported in Table 1 of Banik et al. Our results highlight several spatial architectures that may help guide precision medicine approaches for HPV(−) HNSCC patients, including architectures that may help stratify patients who may have shorter PFS, and thus warrant more aggressive therapy or clinical follow-ups. While our results provide evidence that the spatial organization of HPV(−) HNSCC tumors correlates with clinical outcomes, future studies with larger cohorts will be needed to evaluate the strength and validity of our observations. Studies with greater representation of anatomic site and stage are also needed to assess the prognostic value of the spatial features identified in this HNSCC cohort. Despite these limitations, this study demonstrates practical analysis strategies that elucidate spatial architecture features for potential use in precision medicine.

**TIME compositional change clustering analysis**

Unsupervised hierarchical clustering of each patient was performed using the normalized change in density of each cell type as the features. Euclidean distance was used to determine distances between observations, and the Ward method was used for the linkage.

**Mixing score analysis**

Keren et al. developed a mixing score to quantify the ratio of neoplastic and immune cell spatial interactions. This score is defined as the number of interactions between neoplastic tumor cells and immune cells divided by the number of interactions between immune cells and another immune cell within a tumor region. We defined there to be an interaction between two cells if their centers were within 15 µm from one another. We used the median mixing score value (0.107) for all primary tumors as the threshold to distinguish between mixed and compartmentalized spatial organization groups. Tumor regions with a mixing score of greater than 0.107 were defined as mixed. Tumor regions with a mixing score of less than 0.107 were defined as compartmentalized. We used a density threshold of less than 250 immune cells per 8002 µm2 to define tumor regions as cold. We chose this threshold to match that used by Keren et al.

**Functional marker bootstrapping analyses**

Bootstrapping analyses involved the following steps. First, one tumor region per eighteen tumor samples was randomly selected. The regions were then split into two groups based on their mixed or compartmentalized spatial architecture designation, and the average proportion of the specified cell population expressing the specified functional marker was calculated for each group. Finally, this process was repeated 100 times, yielding 100 values representing the proportion of the specified cell population expressing the specified functional marker for mixed tumor regions and 100 values representing the proportion of the specified cell population expressing the specified functional marker for compartmentalized tumor regions. These values were then compared between the mixed and compartmentalized groups for differences.

**Cellular neighborhood clustering analyses**

Cellular neighborhoods were defined by drawing a circle of a specified radius around all seed cells of a given phenotype. Cells whose centers were inside the circle were considered neighbors of that seed cell and contributed to that cell's neighborhood. All neighborhoods across all tumor regions were then clustered using scikit-learn's MiniBatchKMeans function to perform K-means clustering according to their normalized cellular composition. The elbow method was used to determine the number of clusters to form. Each resulting cluster was comprised of neighborhoods with a similar cellular makeup. Unsupervised hierarchical clustering of each primary tumor was performed using the log10 + 1 normalized proportion (out of 100) of ASMA+ cell neighborhood clusters present in the tumor as the features. Euclidean distance was used to determine distances between observations, and the Ward method was used for the linkage.

**Statistics**

Independent t-tests were used to determine statistically significant differences for independent samples whose differences followed a normal distribution. Mann–Whitney U-tests were used to determine statistically significant differences for independent samples whose differences did not follow a normal distribution. Paired t-tests were used to determine statistically significant differences for paired samples whose differences followed a normal distribution. Wilcoxon signed rank tests were used to determine statistically significant differences for paired samples whose differences did not follow a normal distribution. One-way ANOVA tests were used to determine statistically significant differences for multi-group

---

**KE Blise et al.**

Published in partnership with The Hormel Institute, University of Minnesota
comparisons. If the ANOVA result was significant, a Tukey honestly significant difference post-hoc test was conducted to determine which groups were significantly different from one another. A Benjamini–Hochberg correction was used to account for multiple hypothesis testing in analyses that involved systematically testing multiple variables. p-values less than 0.05 were considered statistically significant. All statistical calculations were performed with the Scipy and statsmodels packages using Python software.

**Survival analyses**

Kaplan–Meier curves were generated and a log-rank test was performed using the lifelines package with Python software. p-values less than 0.05 were considered statistically significant.

**Reporting summary**

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**DATA AVAILABILITY**

All of the data produced by our miHC computational image processing pipeline, including protein abundance, cell phenotype, and cell location information saved in the form of a matrix, in addition to survival data, is available for download on Zenodo at https://doi.org/10.5281/zenodo.5540356.

**CODE AVAILABILITY**

All computational analyses in this study were performed using Python software, version 3.6.5. The code created to produce the results of this study is available at https://github.com/KBlise/HNSCC_miHC_paper.

Received: 14 May 2021; Accepted: 7 January 2022; Published online: 25 February 2022

**REFERENCES**

1. Binniewes, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541–550 (2018).
2. Juntilla, M. R. & de Sauvage, F. J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346–354 (2013).
3. Petitprez, J. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556–560 (2020).
4. Keren, L. et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell 174, 1373–1387 (2018).
5. Ali, H. R. et al. Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer. Nat. Cancer 1, 163–175 (2020).
6. Jackson, H. W. et al. The single-cell pathology landscape of breast cancer. Nature 578, 615–620 (2020).
7. Schuch, C. M. et al. Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front. Cell 182, 1341–1359 (2020).
8. Farkkila, A. et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat. Commun. 11, 1459 (2020).
9. Barua, S. et al. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer. Lung Cancer 117, 73–79 (2018).
10. Gide, T. N. et al. Close proximity of immune and tumor cells underlies response to anti-PD-1-based therapies in metastatic melanoma patients. Oncoimmunology 9, 1659093 (2020).
11. Giraldo, N. A. et al. Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J. Immunother. Cancer 6, 99 (2018).
12. Johnson, D. B. et al. Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR IDO-1 predicts improved outcomes of anti-PD-1 therapies in metastatic melanoma. Clin. Cancer Res. 24, 5250–5260 (2018).
13. Enfeldt, K. S. S. et al. Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence. J. Immunother. Cancer 7, 13 (2019).
14. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
15. Galon, J. et al. Cancer classification using the Immunoscore: a worldwide task force. J. Transl. Med. 10, 205 (2012).

16. Tsujikawa, T. et al. Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis. Cell Rep. 19, 203–217 (2017).
17. Bankit, G. et al. High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers. Methods Enzymol. 635, 1–20 (2020).
18. Eng, J. et al. Cyclic multiplexed-immunofluorescence (cmif), a highly multiplexed method for single-cell analysis. Methods Mol. Biol. 2055, 521–562 (2020).
19. Brucher, B. L. & Jamall, I. S. Cell-cell communication in the tumor microenvironment, carcinogenesis, and anticancer treatment. Cell. Physiol. Biochem. 34, 213–243 (2014).
20. Alshafi, E. et al. Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis. 10, 540 (2019).
21. Cohen, E. E. W. et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J. Immunother. Cancer 7, 184 (2019).
22. Canning, M. et al. Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy. Front. Cell Dev. Biol. 7, 52 (2019).
23. Fakhry, C. et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl Cancer Inst. 100, 261–269 (2008).
24. Ang, K. K. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363, 24–35 (2010).
25. Predina, J. et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc. Natl Acad. Sci. USA 110, E415–E424 (2013).
26. Zheng, B. et al. Changes in the tumor immune microenvironment in resected recurrent soft tissue sarcomas. Ann. Transl. Med. 7, 387 (2019).
27. Walens, A. et al. Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence. Nat. Commun. 11, 5017 (2020).
28. Watermann, C. et al. Recurrent HNSCC harbor an immunosuppressive tumor immune microenvironment suggesting successful tumor immune evasion. Clin. Cancer Res. 27, 632–644 (2021).
29. Hartman, D. J., Ahmad, F., Ferris, R. L., Rimm, D. L. & Pantanowitz, L. Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral. Oncol. 86, 278–287 (2018).
30. Barua, S. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556–560 (2020).
31. Nasman, A. et al. Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS ONE 7, e38711 (2012).
32. Nordfors, C. et al. CD8+ and CD4+ tumor infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after post-operative chemoradiotherapy: a multicentre study of the German cancer consortium radiation oncology group (DOKTK-ROG). Int. J. Cancer 138, 171–181 (2016).
33. Waterman, C. et al. Recurrent HNSCC harbor an immunosuppressive tumor immune microenvironment suggesting successful tumor immune evasion. Clin. Cancer Res. 27, 632–644 (2021).
34. Hartman, D. J., Ahmad, F., Ferris, R. L., Rimm, D. L. & Pantanowitz, L. Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral. Oncol. 86, 278–287 (2018).
35. Barua, S. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556–560 (2020).
36. Ali, H. R. et al. Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer. Nat. Cancer 1, 163–175 (2020).
37. Jackson, H. W. et al. The single-cell pathology landscape of breast cancer. Nature 578, 615–620 (2020).
38. Schuch, C. M. et al. Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front. Cell 182, 1341–1359 (2020).
39. Farkkila, A. et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat. Commun. 11, 1459 (2020).
40. Barua, S. et al. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer. Lung Cancer 117, 73–79 (2018).
41. Gide, T. N. et al. Close proximity of immune and tumor cells underlies response to anti-PD-1-based therapies in metastatic melanoma patients. Oncoimmunology 9, 1659093 (2020).
42. Giraldo, N. A. et al. Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J. Immunother. Cancer 6, 99 (2018).
43. Johnson, D. B. et al. Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO-1 predicts improved outcomes of anti-PD-1 therapies in metastatic melanoma. Clin. Cancer Res. 24, 5250–5260 (2018).
44. Enfeldt, K. S. S. et al. Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence. J. Immunother. Cancer 7, 13 (2019).
45. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
46. Galon, J. et al. Cancer classification using the Immunoscore: a worldwide task force. J. Transl. Med. 10, 205 (2012).

Published in partnership with The Hormel Institute, University of Minnesota
45. Gyanchandani, R. et al. Intratumor heterogeneity affects gene expression profile test prognostic risk stratification in early breast cancer. Clin. Cancer Res. 22, 5362–5369 (2016).
46. Chung, C. H. et al. Molecular subtypes in head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5, 489–500 (2004).
47. Walter, V. et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS ONE 8, e56823 (2013).
48. Parajuli, H. et al. Integrin alpha11 is overexpressed by tumour stroma of head and neck squamous cell carcinoma and correlates positively with alpha smooth muscle actin expression. J. Oral Pathol. Med. 46, 267–275 (2017).
49. Zhang, Q. et al. Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals distinct cancer-associated fibroblasts in head and neck squamous cell carcinoma. Ann. Transl. Med. 9, 1017 (2021).
50. Lim, K. P. et al. Fibroblast gene expression profile reflects the stage of tumour progression in oral squamous cell carcinoma. J. Pathol. 223, 459–469 (2011).
51. Shiga, K. et al. Cancer-associated fibroblasts: their characteristics and their roles in tumour growth. Cancers 7, 2443–2458 (2015).
52. Tao, L., Huang, G., Song, H., Chen, Y. & Chen, L. Cancer associated fibroblasts: an essential role in the tumor microenvironment. Oncol. Lett. 14, 2611–2620 (2017).
53. Sahai, E. et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 20, 174–186 (2020).
54. Johansson, A. C. et al. Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma. Mol. Cancer Res. 10, 1158–1168 (2012).
55. Rodriguez, A. B. et al. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. 36, 109422 (2021).
56. Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561–565 (2020).
57. Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549–555 (2020).
58. Fuji, N. et al. Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance. J. Oral Pathol. Med. 41, 444–451 (2012).
59. Gok Yavuz, B. et al. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1(+) TAMs. Sci. Rep. 9, 3172 (2019).
60. Markwell, S. M. & Weed, S. A. Tumor and stromal-based contributions to head and neck squamous cell carcinoma invasion. Cancers 7, 382–406 (2015).
61. Munir, H. et al. Stromal-driven and Amyloid beta-dependent induction of neutrophil extracellular traps modulates tumor growth. Nat. Commun. 12, 683 (2021).
62. Cong, X. et al. CD66b(+) neutrophils and alpha-SMA(+) fibroblasts predict clinical outcomes and benefits from postoperative chemotherapy in gastric adenocarcinoma. Cancer Med. 9, 2761–2773 (2020).
63. Gaggioli, C. et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhogTIPases in leading and following cells. Nat. Cell Biol. 9, 1392–1400 (2007).
64. Goetz, J. G. et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 146, 148–163 (2011).
65. Lin, J. R., Fallahi-Sichani, M. & Sorgor, P. K. Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method. Nat. Commun. 6, 8390 (2015).
66. Lin, J. R. et al. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. Elife 7, e31657 (2018).
67. Virtanen, P. et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat. Methods 17, 261–272 (2020).
68. Pedregosa, F. et al. Scikit-learn: machine learning in python. JMLR 12, 2825–2830 (2011).
69. Seabold, S. & Perktold, J. statsmodels: econometric and statistical modeling with python. In Proceedings of the 9th Python in Science Conference (2010). https://www.statsmodels.org/stable/index.html#citation.
70. Davidson-Pilon, C. lifelines: survival analysis in Python. J. Open Source Softw. 4, 1317 (2019).